SOURCE: Benda Pharmaceutical, Inc.

November 20, 2007 12:29 ET

Benda Revenue Up 61% to $7.6 Million for Quarter Ended September 30, 2007

HUBEI PROVINCE, CHINA--(Marketwire - November 20, 2007) - Benda Pharmaceutical, Inc. ("Benda" or the "Company") (OTCBB: BPMA), a China-based pharmaceutical company producing traditional Chinese and conventional medicines, as well as Gendicine®, the world's first commercialized gene therapy medicine for the treatment of cancer, announced operating results for the quarter ended September 30, 2007.

Benda reported revenue of approximately $7.6 million for the three months ended September 30, 2007, compared to approximately $4.7 million for the three months ended September 30, 2006 -- a 61% increase. For the nine months ended September 30, 2007, Benda reported revenue of approximately $15.8 million, compared to approximately $12.4 million for the nine months ended September 30, 2006 -- a 27% increase. The increase in revenue was primarily due to the sales of additional products at the Benda Ebei plant, whose nine month revenue increased by $4.2 million, or 55%, from 2006 to 2007. The acquisition of a 60.1% stake in SiBiono in early April 2007 also added $3.0 million to Benda's total revenue for the nine months ended September 2007.

Benda reported net income of approximately $900,000 for the three months ended September 30, 2007, compared to net income of approximately $1.8 million for the three months ended September 30, 2006 -- a 50% decrease. The decrease in net income was mainly due to approximately $1.3 million in non-cash expenses, consisting of approximately $1.0 million in non-cash debt discount amortization interest charges associated with the SiBiono acquisition and approximately $300,000 associated with the cashless exercise of warrants. Excluding these non-cash charges, Benda would have reported $2.2 million in net income for the three months ended September 30, 2007 -- a 24% increase over the comparative quarter last year.

Benda reported a net loss of approximately $7.6 million for the nine months ended September 30, 2007, compared to net income of approximately $3.0 million for the nine months ended September 30, 2006. The decrease in net income was primarily due to approximately $8.2 million in non-cash stock compensation expenses and approximately $1.9 million in non-cash debt discount amortization interest charges, both of which were incurred as part of the acquisition of the majority interest of SiBiono in early April 2007. Excluding these extraordinary items, Benda would have reported $2.5 million in net income for the nine months ended September 30, 2007 -- a 17% decease for the comparative period last year.

Third Quarter Earnings Conference Call

Benda will host a conference call on Wednesday, November 28, 2007 to review third quarter 2007 earnings results. The conference call is scheduled for 9:00 a.m. Eastern Time. To participate in the call, please dial:

          U.S. and Canada:   1 (800) 289-0544
          International:     1 (913) 981-5533
          Conference ID:     7048368

A replay of the call will be available at 12:00 p.m. Eastern Time. You will be able to access it at any time through the Benda Website at www.BendaPharma.com, or by phone until midnight December 28, 2007. To access the replay by phone, please dial:

          U.S. and Canada:   1 (888) 203-1112
          International:     1 (719) 457-0820
          Conference ID:     7048368

About Benda Pharmaceutical, Inc.

Benda Pharmaceutical, Inc. (www.bendapharma.com), a China-based pharmaceutical company, is a pure play on explosive Chinese pharmaceutical spending and the global search for a cancer cure. Benda produces traditional Chinese and conventional medicines, as well as Gendicine®, the world's first commercialized gene therapy medicine for the treatment of cancer.

Benda Investor Resources

Fact Sheet:

http://files.shareholder.com/downloads/BPMA/151228937x4452657x111082/95430c49-a77a-43c9-89ad-d6cc75cffc59/FactSheet.pdf

PowerPoint Presentation:

http://files.shareholder.com/downloads/BPMA/151228937x4452657x111087/35a10e95-f328-45ad-81ab-529f6cc1af6d/Bendapresentation061107.pdf

Gendicine® Video:

http://play.rbn.com/play.asx?url=shareholder/shareholder/wmdemand/bendavideo.wmv&proto=mms?mswmext=.asx

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact Information